Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Celgene Rises as European Commission OKs Merger With Bristol-Myers

Published 07/29/2019, 11:33 AM
Updated 07/29/2019, 01:58 PM
© Reuters.

Investing.com - Celgene (NASDAQ:CELG) was higher in midday trade on Monday after the European Union Commission gave its blessing for the biopharmaceutical company to merge with Bristol-Myers Squibb (NYSE:BMY).

The approval from the commission is just one of a few regulatory hurdles the company faces before the acquisition is completed.

“Clearance from the European Commission is an important milestone toward completing our combination with Celgene and moves us one step closer to creating a leading biopharma company that is well positioned to develop and deliver innovative, meaningful medicines to patients,” said Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb.

Bristol-Myers intends to close the deal by the beginning of 2020 at the latest. The acquisition was announced in January but has yet to be approved by the U.S. Federal Trade Commission.

Shares of Celgene (NASDAQ:CELG) rose 0.3%, while Bristol-Myers gained 0.2%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.